<DOC>
	<DOCNO>NCT00561392</DOCNO>
	<brief_summary>This study evaluate safety efficacy 10 cm^2 rivastigmine patch patient Alzheimer Disease ( MMSE 10-26 ) . The primary objective percentage patient stay target size 10 cm^2 least 8 week . This proportion compare historical data percentage patient could reach rivastigmine capsule target dose 12 mg stay least 8 week .</brief_summary>
	<brief_title>Clinical Effectiveness 10 cm^2 Rivastigmine Patch Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Males , female childbearing potential ( surgically sterile least one year postmenopausal ) , least 50 year age Probable Alzheimer 's disease accord NINCDSADRDA ( National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ) DSMIV ( Diagnostic Statistical Manual Mental Disorders ) criterion MMSE ( MiniMental State Examination ) score &gt; 10 &lt; 26 Patients initiate therapy first time cholinesterase inhibitor ( patient prescribe rivastigmine memantine allow ) Patients fail benefit previous cholinesterase inhibitor treatment Patients treat accord product monograph rivastigmine capsule patient involve clinical trial Current diagnosis active skin lesion/disorder would prevent accurate assessment adhesion potential skin irritation patch ( e.g. , atopic dermatitis , wound scratch skin area patch application ) Other protocoldefined exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Patch</keyword>
</DOC>